Loading
A phase 3 trial of Atezolizumab, Bevacizumab, Tiragolumab in hepatocellular carcinoma, run by Hoffmann-La Roche, active and no longer recruiting.
A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152) is a phase 3 interventional study registered as NCT05904886 by Hoffmann-La Roche, with 687 participants enrolled, started 2023-09-14 and due to reach its primary completion in 2025-05-08. Interventions recorded: Atezolizumab, Bevacizumab, Tiragolumab, Placebo. Conditions listed: Hepatocellular Carcinoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Advanced hepatocellular carcinoma (BCLC C), Atezolizumab, Roche / Genentech, Bevacizumab.
Shares Atezolizumab, Roche / Genentech, Bevacizumab, Anti-angiogenic therapy.
Shares Tiragolumab, Advanced hepatocellular carcinoma (BCLC C), Atezolizumab, Roche / Genentech.
Shares TIGIT blockade, Tiragolumab, Atezolizumab, Roche / Genentech.
Shares Advanced hepatocellular carcinoma (BCLC C), Atezolizumab, Bevacizumab, Anti-angiogenic therapy.
Shares Immunotherapy downstaging to transplant with a safe washout, Advanced hepatocellular carcinoma (BCLC C), Atezolizumab, Anti-angiogenic therapy.
Shares Advanced hepatocellular carcinoma (BCLC C), Bevacizumab, Anti-angiogenic therapy, Monoclonal antibodies.
Shares Advanced hepatocellular carcinoma (BCLC C), Bevacizumab, Anti-angiogenic therapy, Monoclonal antibodies.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/